コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nderlying chronic lymphocytic leukemia/small lymphocytic lymphoma.
2 ctory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
3 nt of chronic lymphocytic leukaemia or small lymphocytic lymphoma.
4 with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
5 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.
6 eated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
7 t-naive and relapsed/refractory CLL or small lymphocytic lymphoma.
8 ocytic leukaemia and two patients with small lymphocytic lymphoma.
9 nts with relapsed or refractory CLL or small lymphocytic lymphoma.
10 eption of chronic lymphocytic leukemia/small lymphocytic lymphoma.
11 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.
12 nd B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
13 -line chronic lymphocytic leukaemia or small lymphocytic lymphoma.
14 0.4, 0.3; p trend = 0.03) with risk of small lymphocytic lymphoma.
15 -cell and chronic lymphocytic leukemia/small lymphocytic lymphomas.
16 cell lymphomas, such as follicular and small lymphocytic lymphomas.
18 -risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with folli
19 odgkin's lymphomas, including cases of small lymphocytic lymphoma (18 cases), marginal zone lymphoma
21 ded follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15),
22 All patients had follicular or small cell lymphocytic lymphoma after relapse from a prior response
23 ctory chronic lymphocytic leukaemia or small lymphocytic lymphoma and at least two previous lines of
24 zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia wi
25 Most of the published data concern chronic lymphocytic lymphoma and diffuse large B-cell lymphoma,
27 n between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 x 1
28 ma (137 diffuse, 58 follicular, and 32 small lymphocytic lymphomas) and 63 cases of B-CLL were identi
31 ymphomas (6 marginal zone lymphomas, 7 small lymphocytic lymphomas, and 13 follicular lymphomas, grad
33 is of chronic lymphocytic leukaemia or small lymphocytic lymphoma as per the International Workshop o
34 splantation was found to have stage IV small lymphocytic lymphoma at the time of transplantation.
35 one lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient sampl
36 homa (Case 1), follicular lymphoma and small lymphocytic lymphoma (Case 2), and mantle cell lymphoma
39 U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL)
40 te lymphoblastic leukemia (ALL), and chronic lymphocytic lymphoma (CLL) patient samples, representing
43 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL s
45 (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other NHL sub
46 rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year.
47 is, RR of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1.08-2.
48 d that chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal NHL sub
49 ma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (
53 , but not chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0.31 to
55 , such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymp
56 mphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL no
57 heimer's disease dataset and a diffuse small lymphocytic lymphoma dataset reveals its ability to iden
58 -risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymp
59 -risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymp
60 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (diffusely positive in 33 cases), w
62 eated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or y
63 ib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse l
64 including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle ce
65 ctory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with
66 CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five clinical trials (Pedi CAR
67 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutations;
68 ctory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the fin
69 ntrast to follicle center lymphoma and small lymphocytic lymphoma; however, pRB expression does not a
71 promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically e
72 with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ran
73 ctory chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients who had experie
74 ts with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk
75 with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features a
76 atic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits further
77 CD20, expressed on greater than 90% of B-lymphocytic lymphomas, is an attractive target for antib
78 ancies (chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom
79 B cells (chronic lymphocytic leukemia/small lymphocytic lymphomas, mantle cell lymphomas, and precur
81 % (mainly chronic lymphocytic leukemia/small lymphocytic lymphoma), monoclonal gammopathy in 20%, and
82 with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to p
83 (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia (n =
84 (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), were enr
85 0), marginal zone lymphoma (n=30), and small lymphocytic lymphoma (n=30) were enrolled from June 30,
86 (n=14 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=10 B-cell non-Hodgkin lymphoma)
87 (n=9 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=13 B-cell non-Hodgkin lymphoma).
90 chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a med
91 vation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell l
92 with chronic lymphocytic leukaemia or small lymphocytic lymphoma reaching undetectable MRD in both p
93 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma received oral ibrutinib 420 mg once
95 1.96) and chronic lymphocytic leukemia/small lymphocytic lymphoma (relative risk = 1.93, 95% confiden
96 naive chronic lymphocytic leukaemia or small lymphocytic lymphoma, required therapy, and were at leas
99 0.78) and chronic lymphocytic leukemia/small lymphocytic lymphoma (RR, 0.46; 95% CI, 0.21-1.01), and
100 efractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk
101 cyte CITE-seq data and matched diffuse small lymphocytic lymphoma scRNA-seq and scATAC-seq data.
104 ded eight chronic lymphocytic leukemia/small lymphocytic lymphomas, six mantle cell lymphomas, seven
105 y (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (F
106 (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that
107 Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the
108 chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase tri
109 chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the
110 icular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukem
111 characterized and its relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic leukem
112 effect was most pronounced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [0.7-15
113 ith chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hou
114 nts with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokin
115 chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous coval
116 62b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed to achieve a humor
117 ith chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The Universi
118 ith chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response
120 treatment-naive (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population of pat
126 as compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic le
127 en reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia
128 omas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglob
129 tumors (10.5%), which included 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular small c
130 sk of the chronic lymphocytic leukemia/small lymphocytic lymphoma subtype among women only (253 cases
132 is of chronic lymphocytic leukaemia or small lymphocytic lymphoma to Richter transformation was 7.6 y
133 e associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance findin
134 ational Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, do
135 with chronic lymphocytic leukaemia or small lymphocytic lymphoma were recruited from two academic ho
136 e CPP32 immunopositive, whereas 3 of 3 small lymphocytic lymphomas were CPP32 negative, suggesting th
137 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who received at least one dose of s
138 ctive chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease
139 n in chronic lymphocytic leukaemia and small lymphocytic lymphoma with treatment duration guided by e
140 actory B-cell acute lymphocytic leukaemia or lymphocytic lymphoma, without increasing the risk of sev
141 for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetec